LRRK2 mutations in Parkinson disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Neurology

• Publication date

  2005-09-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/01.wnl.0000169023.51764.b0PMID 16157908
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A common LRRK2 mutation in idiopathic Parkinson's disease.

  2005cited by this paper
• Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations.

  2005cited by this paper
• A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.

  2005cited by this paper
• Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease.

  2005cited by this paper
• Mixed-lineage kinases: a target for the prevention of neurodegeneration.

  2004cited by this paper
• Genetic clues to the pathogenesis of Parkinson's disease

  2004cited by this paper
• Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

  2004cited by this paper
• Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

  2004cited by this paper
• The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins?

  2003cited by this paper
• Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990

  1999cited by this paper

• Precision medicine in neurodegenerative diseases: From research to clinical practice.

  2025cites this paper
• Global prevalence and incidence of Young Onset Parkinson's disease: A systematic review and meta-analysis.

  2024cites this paper
• Lysosome quality control in health and neurodegenerative diseases

  2024cites this paper
• Emerging Perspectives on Prime Editor Delivery to the Brain

  2024cites this paper
• Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.

  2024cites this paper
• Genetic Evidence for Endolysosomal Dysfunction in Parkinson’s Disease: A Critical Overview

  2023cites this paper
• Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study

  2023influential citation
• Structural insight into G2019S mutated LRRK2 kinase and brain-penetrant type I inhibitor complex: a molecular dynamics approach

  2023cites this paper
• Role of the Residue Q1919 in Increasing Kinase Activity of G2019S LRRK2 Kinase: A Computational Study.

  2023cites this paper
• Hornerin deposits in neuronal intranuclear inclusion disease: direct identification of proteins with compositionally biased regions in inclusions

  2022cites this paper
• Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review.

  2022cites this paper
• Discovery of azaspirocyclic 1H-3,4,5-Trisubstitued pyrazoles as novel G2019S-LRRK2 selective kinase inhibitors.

  2022cites this paper
• Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson’s disease

  2022cites this paper
• Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.

  2021cites this paper
• LRRK2 in Parkinson disease: challenges of clinical trials

  2020cites this paper
• Mutation Analysis of the Genes Associated with Parkinson’s Disease in a Finnish Cohort of Early-Onset Dementia

  2020cites this paper
• Sex differences in movement disorders

  2020cites this paper
• Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

  2020cites this paper
• Gender differences in prevalence of LRRK2-associated Parkinson disease：A meta-analysis of observational studies.

  2019cites this paper
• LRRK2 and mitochondria: Recent advances and current views.

  2019cites this paper
• Sphingolipids in the Pathogenesis of Parkinson's Disease and Parkinsonism.

  2019cites this paper
• A Comprehensive Analysis of Population Differences in LRRK2 Variant Distribution in Parkinson's Disease

  2019cites this paper
• Biomarkers of Parkinson's Disease

  2019cites this paper
• Genetic analysis of Mendelian mutations in a large UK population-based Parkinson’s disease study

  2019cites this paper
• Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner

  2019cites this paper
• P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity.

  2018cites this paper
• Self-report data as a tool for subtype identification in genetically-defined Parkinson’s Disease

  2018cites this paper
• Genetic analysis of LRRK2 in Parkinson's disease in Han Chinese population.

  2018cites this paper
• Sleep disorders and Parkinson disease; lessons from genetics.

  2018cites this paper
• Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease

  2018cites this paper
• CSF lamp2 concentrations are decreased in female Parkinson's disease patients with LRRK2 mutations.

  2018cites this paper
• Nonmotor Signs in Genetic Forms of Parkinson's Disease.

  2017cites this paper
• The relevance of gender in Parkinson’s disease: a review

  2017cites this paper
• Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder.

  2017cites this paper
• Post-transcriptional regulation of alpha-synuclein by leucine-rich repeat kinase 2 and micro-RNAs with implications for Parkinson's disease

  2016cites this paper
• Genetics in Parkinson disease: Mendelian versus non‐Mendelian inheritance

  2016cites this paper
• How Research on Human Progeroid and Antigeroid Syndromes Can Contribute to the Longevity Dividend Initiative.

  2016cites this paper
• Protein Structure Modeling of Abnormal Genes Associated with PARK 1 and PARK 8 Loci Related to Autosomal Dominant Parkinson’s Disease and Docking the Protein(s) with Appropriate Ligands

  2016cites this paper
• Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson’s disease

  2015cites this paper
• LRRK2 dephosphorylation increases its ubiquitination

  2015cites this paper
• Does α-synuclein have a dual and opposing effect in preclinical vs. clinical Parkinson's disease?

  2014cites this paper
• Brain Iron Homeostasis: From Molecular Mechanisms To Clinical Significance and Therapeutic Opportunities

  2014cites this paper
• LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status

  2014cites this paper
• Neural stem cells in Parkinson’s disease: a role for neurogenesis defects in onset and progression

  2014cites this paper
• Metabolic control of cell death

  2014cites this paper
• Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)

  2014cites this paper
• Genetic susceptibility loci, environmental exposures, and Parkinson's disease: a case-control study of gene-environment interactions.

  2013cites this paper
• Development of Inducible Leucine-rich Repeat Kinase 2 (LRRK2) Cell Lines for Therapeutics Development in Parkinson’s Disease

  2013cites this paper
• Pyrazolopyridines pour le traitement de la maladie de parkinson

  2013cites this paper
• MODELING LRRK2-ASSOCIATED PARKINSON’S DISEASE IN C. ELEGANS

  2012cites this paper
• Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

  2012cites this paper
• Quantitative assessment of the effect of LRRK2 exonic variants on the risk of Parkinson's disease: a meta-analysis.

  2012cites this paper
• Ablation of serum response factor in dopaminergic neurons exacerbates susceptibility towards MPTP‐induced oxidative stress

  2012cites this paper
• LRRK2 Parkinson’s disease: from animal models to cellular mechanisms

  2011cites this paper
• Pyrazolopyridines en tant qu'inhibiteurs de la kinase lrrk2

  2011cites this paper
• Clinical and brain imaging characteristics in leucine‐rich repeat kinase 2–associated PD and asymptomatic mutation carriers

  2011cites this paper
• Models for LRRK2-Linked Parkinsonism

  2011influential citation
• Pyrazolopyridines comme inhibiteurs de la kinase lrrk2

  2011cites this paper
• Genetic Testing and Parkinson Disease: Assessment of Patient Knowledge, Attitudes, and Interest

  2011cites this paper
• Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.

  2011cites this paper
• Epidemiology and etiology of Parkinson’s disease: a review of the evidence

  2011cites this paper
• Genetics of Parkinson's Disease—An Overview

  2010cites this paper
• Parkinson's disease: Exit toxins, enter genetics

  2010cites this paper
• Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review.

  2010cites this paper
• Transgenic mouse models of Parkinson's disease and Huntington's disease.

  2010cites this paper
• Neurochemistry changes associated with mutations in familial Parkinson's disease.

  2010cites this paper
• Genetic Etiology of Parkinson Disease Associated with Mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 Genes: A Mutation Update

  2010cites this paper
• LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.

  2010cites this paper
• Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2.

  2010cites this paper
• Function of LRRK2 in Parkinson's Disease*: Function of LRRK2 in Parkinson's Disease*

  2010cites this paper
• The Parkinson disease‐associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro

  2009cites this paper
• Clinical and pathological characteristics of patients with Leucine‐rich repeat kinase‐2 mutations

  2009cites this paper
• The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews

  2009influential citation
• LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease.

  2009cites this paper
• Proteomics in animal models of Alzheimer's and Parkinson's diseases.

  2009cites this paper
• Lrrk2 R1441G-related Parkinson’s disease: evidence of a common founding event in the seventh century in Northern Spain

  2009cites this paper
• The G2019S LRRK2 Mutation is Rare in Korean Patients with Parkinson's Disease and Multiple System Atrophy

  2009cites this paper
• Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein.

  2009cites this paper
• Parkinson's disease: from monogenic forms to genetic susceptibility factors.

  2009cites this paper
• Relative contribution of simple mutations vs. copy number variations in five Parkinson disease genes in the Belgian population

  2009cites this paper
• LRRK2 and neurodegeneration

  2009cites this paper
• CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity

  2009cites this paper
• Factors patogènics convergents en taupaties

  2009influential citation
• Parkinson-Linked Genes and Toxins That Affect Neuronal Cell Death Through the Bcl-2 Family

  2009cites this paper
• Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations

  2008cites this paper
• Progress in neuroprotection in Parkinson’s disease

  2008cites this paper
• The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2

  2008cites this paper
• Mitochondria in the aetiology and pathogenesis of Parkinson's disease.

  2008cites this paper
• The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules

  2008cites this paper
• Is the G2019S LRRK2 mutation common in all southern European populations?

  2008cites this paper
• Characterization of the Parkinson's Disease Associated Protein, Leucine-Rich Repeat Kinase 2 (LRRK2), as a Ras-Related GTPase

  2008cites this paper
• TheChaperoneActivityofHeatShockProtein90IsCritical forMaintainingtheStabilityofLeucine-RichRepeat Kinase2

  2008cites this paper
• Genetic Epidemiology of Parkinson disease

  2008cites this paper
• Untersuchung des Expressionsmusters und der Neuropathologie konditionaler Mausmodelle des Morbus Parkinson

  2008cites this paper
• The Roc Domain of Leucine-Rich Repeat Kinase 2 ( LRRK 2 ) is Sufficient for Interaction with Microtubules

  2008cites this paper
• RNA interference of LRRK2–microarray expression analysis of a Parkinson’s disease key player

  2008cites this paper
• Mitochondrial Medicine for Aging and Neurodegenerative Diseases

  2008cites this paper
• LRRK2 Screening in a Canadian Parkinson's Disease Cohort

  2007cites this paper
• Impact of recent genetic findings in Parkinson's disease

  2007cites this paper
• LRRK2 and Parkinsons disease in Norway

  2007cites this paper